Strategic Acquisition Trilogy is now part of Indegene, combining clinical writing expertise with broader life sciences commercialization capabilities, which suggests potential for integrated service offerings and joint go-to-market strategies.

Regulatory Focus Specialization in clinical regulatory documentation positions Trilogy to be a preferred partner for early and late-stage pharma projects seeking compliant, narratively strong submissions that accelerate review timelines.

Global Footprint Distributed team across Germany, the UK, and the US enables nearshore and offshore collaboration, presenting opportunities for cross-border projects, 24/7 coverage, and local-market support for multinational clients.

Scale and Talent With a sizable pool of experienced writers and a track record of coordinating entire documentation programs, there is potential to upsell end-to-end manuscript development, health authority filings, and program-wide documentation suites.

Financial Upsell Revenue scale indicates capability to engage larger pharma and CRO partners for expanded services, including process consulting, template standardization, and integrated documentation platforms within Indegene’s ecosystem.